Skip to content

TWICE WEEKLY VERSUS WEEKLY HIGH DOSE RATE BRACHYTHERAPY IN LOCALLY ADVANCED CARCINOMA CERVIX

COMPARISON OF TREATMENT RESULTS IN LOCALLY ADVANCED CARCINOMA CERVIX BY TWICE WEEKLY VERSUS WEEKLY HIGH DOSE RATE BRACHYTHERAPY - Twice weekly brachy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013338
Enrollment
94
Registered
2018-04-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Locally Advanced Carcinoma Cervix

Interventions

Intervention1: Twice weekly High dose Rate Brachytherapy: 4.2 Gy per fraction, 2 fractions in a week (on Tuesdays and Fridays), total 6 Fractins Control Intervention1: Weekly High dose Rate Brachyther

Sponsors

Dr Barnini Ghosh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histopathology confirmed newly diagnosed primary squamous cell carcinoma of cervix 2. Stage of the disease should be between IIB to IVA 3. Patient should have ECOG performance status less than or equal to 2 4. Patient must be medically suitable for concurrent chemoradiation and brachytherapy 5. Patient must sign a study specific informed consent prior to study entry 6. Routine blood reports like complete haemogram, renal function test and liver function test within normal range

Exclusion criteria

Exclusion criteria: 1. Histopathology other than squamous cell carcinoma 2. Evidence of distant metastasis by clinical or radiological examination 3. Previous radiotherapy or concurrent chemoradiation within the intended treatment volume 4. Previous chemotherapy or definitive surgery for the tumour under study other than biopsy 5. Any other serious illness or major organ dysfunction

Design outcomes

Primary

MeasureTime frame
To compare the response rates between the patients in the 2 armsTimepoint: 6 weeks

Secondary

MeasureTime frame
To detect recurrence, if anyTimepoint: 1.5 years;To determine Acute Toxicities according to the RTOG Criteria and CTCAE version 4Timepoint: 90 days;To determine Late Toxicities according to the RTOG Criteria and CTCAE version 4Timepoint: 1.5 years

Countries

India

Contacts

Public ContactDr Barnini Ghosh

Medical College and Hospital, Kolkata

asitrdeb@rediffmail.com9830583960

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026